Table 5 HR with 95% CI for iPFS in patients with EGFR-mutant NSCLC and brain metastases.

From: First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis

1G EGFR-TKIs

    

2.21 (1.81–2.69)*

3G EGFR-TKIs

   

2.78 (1.91–4.04)*

1.26 (0.82–1.93)

1G EGFR-TKIs + CT

  

3.80 (2.10–6.89)*

1.72 (0.99–3.02)

1.37 (0.68–2.76)

3G EGFR-TKIs + CT

 

5.56 (1.52–20.34)*

2.52 (0.68–9.36)

2.00 (0.52–7.72)

1.46 (0.35–6.08)

1G EGFR-TKIs + VEGF mAb

  1. HR: hazard ratio; CI: confidence intervals; iPFS: intracranial progression-free survival; NSCLC: non-small cell lung cancer; 1G/3G EGFR-TKIs: first/third-generation epidermal growth factor receptor tyrosine kinase inhibitors; VEGF mAbs: vascular endothelial growth factor monoclonal antibodies; CT: chemotherapy.
  2. *Represents a statistically significant difference in HR values
Back to article page